Wire · opportunities
Compass points to unmet need in depression as landmark psychedelic nears market
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
Compass Pathways is preparing to launch COMP360, a psilocybin-based therapy for treatment-resistant depression (TRD) in the U.S., supported by new survey data highlighting the significant unmet needs of TRD patients and their caregivers. The therapy aims to become the first FDA-approved classic psychedelic treatment, with ongoing efforts to educate healthcare providers and raise awareness of TRD.
This Wire brief sits within Fusion42's coverage of Mental Health, and 2 sources have reported it between 21 Oct 2026 and 2 Nov 2026.
◆ ◆ The Wire takeaway
You are about to see the first classic psychedelic treatment reach the U.S. market for depression, which will open new routes to treat mental health beyond traditional drugs. Prepare to engage with healthcare providers who will need education to consider this new approach.
◆ Coverage
2 sources · first reported 21 Oct 2026 · latest 2 Nov 2026
◆ Related on Wire
◆ Topics